TORONTO , Dec. 19, 2024 /CNW/ - RBC Global Asset Management Inc. ("RBC GAM Inc.") today announced estimated December 2024 cash distributions for unitholders of RBC ETFs and ETF Series of RBC Funds. Please note that these are estimated amounts only, as of December 13, 2024 . The estimates could change if the RBC ETFs or ETF Series of RBC Funds, as applicable, experience subscriptions or redemptions prior to the ex-dividend date or for other unforeseen factors. RBC GAM Inc. expects to announce final December 2024 monthly cash distributions for RBC ETFs and ETF Series of RBC Funds on or about December 30, 2024 . Unitholders of record on December 30, 2024 , will receive distributions payable on January 6, 2025 . The actual taxable amounts of cash and reinvested distributions for 2024, including the tax characteristics of the distributions, will be reported to brokers (through CDS Clearing and Depository Services Inc.) in early 2025. The estimated December 2024 cash distribution amounts per unit for the RBC ETFs are as follows: FUND NAME FUND TICKER ESTIMATED CASH DISTRIBUTION PER UNIT RBC 1-5 Year Laddered Canadian Bond ETF RLB $0.050 RBC 1-5 Year Laddered Canadian Corporate Bond ETF RBO $0.070 RBC Target 2025 Canadian Government Bond ETF RGQN $0.035 RBC Target 2026 Canadian Government Bond ETF RGQO $0.040 RBC Target 2027 Canadian Government Bond ETF RGQP $0.035 RBC Target 2028 Canadian Government Bond ETF RGQQ $0.045 RBC Target 2029 Canadian Government Bond ETF RGQR $0.055 RBC Target 2030 Canadian Government Bond ETF RGQS $0.020 RBC Target 2025 Canadian Corporate Bond Index ETF RQN $0.060 RBC Target 2026 Canadian Corporate Bond Index ETF RQO $0.040 RBC Target 2027 Canadian Corporate Bond Index ETF RQP $0.050 RBC Target 2028 Canadian Corporate Bond Index ETF RQQ $0.070 RBC Target 2029 Canadian Corporate Bond Index ETF RQR $0.080 RBC Target 2030 Canadian Corporate Bond Index ETF RQS $0.062 RBC Target 2025 U.S. Corporate Bond ETF RUQN $0.045 RBC Target 2025 U.S. Corporate Bond ETF (USD Units)* RUQN.U $0.032 RBC Target 2026 U.S. Corporate Bond ETF RUQO $0.040 RBC Target 2026 U.S. Corporate Bond ETF (USD Units)* RUQO.U $0.028 RBC Target 2027 U.S. Corporate Bond ETF RUQP $0.045 RBC Target 2027 U.S. Corporate Bond ETF (USD Units)* RUQP.U $0.032 RBC Target 2028 U.S. Corporate Bond ETF RUQQ $0.055 RBC Target 2028 U.S. Corporate Bond ETF (USD Units)* RUQQ.U $0.039 RBC Target 2029 U.S. Corporate Bond ETF RUQR $0.060 RBC Target 2029 U.S. Corporate Bond ETF (USD Units)* RUQR.U $0.042 RBC Target 2030 U.S. Corporate Bond ETF RUQS $0.040 RBC Target 2030 U.S. Corporate Bond ETF (USD Units)* RUQS.U $0.028 RBC Canadian Discount Bond ETF RCDB $0.030 RBC PH&N Short Term Canadian Bond ETF RPSB $0.060 RBC U.S. Discount Bond ETF RUDB $0.020 RBC U.S. Discount Bond ETF (USD Units)* RUDB.U $0.014 RBC U.S. Discount Bond (CAD Hedged) ETF RDBH $0.020 RBC Short Term U.S. Corporate Bond ETF RUSB $0.085 RBC Short Term U.S. Corporate Bond ETF (USD Units)* RUSB.U $0.060 RBC Canadian Preferred Share ETF RPF $0.095 RBC Quant Canadian Dividend Leaders ETF RCD $0.090 RBC Canadian Dividend Covered Call ETF RCDC $0.115 RBC Canadian Bank Yield Index ETF RBNK $0.100 RBC Quant U.S. Dividend Leaders ETF RUD $0.023 RBC Quant U.S. Dividend Leaders ETF (USD Units)* RUD.U $0.016 RBC Quant U.S. Dividend Leaders (CAD Hedged) ETF RUDH $0.025 RBC U.S. Dividend Covered Call ETF RUDC $0.101 RBC U.S. Dividend Covered Call ETF (USD Units)* RUDC.U $0.071 RBC U.S. Banks Yield Index ETF RUBY $0.060 RBC U.S. Banks Yield Index ETF (USD Units)* RUBY.U $0.042 RBC U.S. Banks Yield (CAD Hedged) Index ETF RUBH $0.075 RBC Quant European Dividend Leaders ETF RPD $0.070 RBC Quant European Dividend Leaders ETF (USD Units)* RPD.U $0.049 RBC Quant European Dividend Leaders (CAD Hedged) ETF RPDH $0.080 RBC Quant EAFE Dividend Leaders ETF RID $0.070 RBC Quant EAFE Dividend Leaders ETF (USD Units)* RID.U $0.049 RBC Quant EAFE Dividend Leaders (CAD Hedged) ETF RIDH $0.080 RBC Quant Emerging Markets Dividend Leaders ETF RXD $0.050 RBC Quant Emerging Markets Dividend Leaders ETF (USD Units)* RXD.U $0.035 * Cash distribution per unit ($) amounts are USD for RUQN.U, RUQO.U, RUQP.U, RUQQ.U, RUQR.U, RUQS.U, RUDB.U, RUSB.U, RUD.U, RUDC.U, RUBY.U, RPD.U, RID.U, and RXD.U The estimated December 2024 cash distribution amounts per unit for ETF Series of RBC Funds are as follows: FUND NAME FUND TICKER ESTIMATED CASH DISTRIBUTION PER UNIT RBC Conservative Bond Pool – ETF Series RCNS $0.150 RBC Core Bond Pool – ETF Series RCOR $0.160 RBC Core Plus Bond Pool – ETF Series RPLS $0.185 RBC Canadian Equity Income Fund – ETF Series RCEI $0.062 RBC North American Value Fund – ETF Series RNAV $0.408 RBC North American Growth Fund – ETF Series RNAG $0.244 RBC U.S. Mid-Cap Growth Equity Fund – ETF Series RUMG $0.000 RBC Life Science and Technology Fund – ETF Series RLST $0.000 RBC International Equity Fund – ETF Series RINT $0.260 RBC Emerging Markets Dividend Fund – ETF Series REMD $0.049 RBC Global Energy Fund – ETF Series RENG $0.534 RBC Global Precious Metals Fund – ETF Series RGPM $0.000 RBC Global Technology Fund – ETF Series RTEC $0.000 Please note that the above estimated cash distributions do not include the annual reinvested capital gains distributions for 2024, which are reported separately. For further information regarding RBC ETFs and ETF Series of RBC Funds, please visit www.rbcgam.com/etfsolutions . Forward-looking information: This notice contains forward-looking statements within the meaning of certain securities laws. Forward-looking statements in this notice include statements with respect to the December 2024 cash distributions for the RBC ETFs and ETF Series of RBC Funds. By their nature, these forward-looking statements require us to make assumptions and are subject to inherent risks and uncertainties, which give rise to the possibility that the actual cash distributions will differ materially from the estimated cash distributions set forth in this notice. Factors that could cause the actual cash distributions to differ from the estimated cash distributions include, but are not limited to: the actual amounts of distributions received by the RBC ETFs and ETF Series of RBC Funds; the actual amounts of capital gains generated from sales of securities; trading activity within the RBC ETFs and ETF Series of RBC Funds, including buying and selling of securities; and subscription and redemption activity. Distribution estimates do not denote the yield a client may receive. All values are expressed in Canadian dollars, unless otherwise indicated. Totals may not sum due to rounding. The December 2024 cash distribution estimates are provided by RBC GAM Inc. and are for information purposes only. They do not reflect final attributions for tax purposes. For more information, please speak with your investment advisor. Commissions, management fees and expenses all may be associated with investments in mutual funds and exchange-traded funds ("ETFs"). Please read the applicable prospectus or ETF Facts document before investing. Mutual funds and ETFs are not guaranteed, their values change frequently and past performance may not be repeated. ETF units are bought and sold at market price on a stock exchange and ETF Series is a class of securities offered by a mutual fund that are bought and sold at market price on a stock exchange. Brokerage commissions will reduce returns. RBC ETFs do not seek to return any predetermined amount at maturity. Index returns do not represent RBC ETF returns. RBC ETFs and RBC Funds are managed by RBC GAM Inc., a member of the RBC GAM group of companies and an indirect wholly-owned subsidiary of Royal Bank of Canada . RBC Target 2025 Canadian Government Bond ETF, RBC Target 2026 Canadian Government Bond ETF, RBC Target 2027 Canadian Government Bond ETF, RBC Target 2028 Canadian Government Bond ETF, RBC Target 2029 Canadian Government Bond ETF and RBC Target 2030 Canadian Government Bond ETF (collectively, the "Canadian TMGB ETFs"), RBC Target 2025 Canadian Corporate Bond Index ETF, RBC Target 2026 Canadian Corporate Bond Index ETF, RBC Target 2027 Canadian Corporate Bond Index ETF, RBC Target 2028 Canadian Corporate Bond Index ETF, RBC Target 2029 Canadian Corporate Bond Index ETF and RBC Target 2030 Canadian Corporate Bond Index ETF (collectively, the "Canadian TMCB ETFs"), and RBC Target 2025 U.S. Corporate Bond ETF, RBC Target 2026 U.S. Corporate Bond ETF, RBC Target 2027 U.S. Corporate Bond ETF, RBC Target 2028 U.S. Corporate Bond ETF, RBC Target 2029 U.S. Corporate Bond ETF and RBC Target 2030 U.S. Corporate Bond ETF (collectively, the "U.S. TMCB ETFs"), do not seek to deliver a predetermined amount at maturity, and the amount an investor receives may be more or less than their original investment. The Canadian TMCB ETFs have been developed solely by RBC GAM Inc., and are not in any way connected to or sponsored, endorsed, sold or promoted by the London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). All rights in the FTSE Canada 2025 Maturity Corporate Bond Index, FTSE Canada 2026 Maturity Corporate Bond Index, FTSE Canada 2027 Maturity Corporate Bond Index, FTSE Canada 2028 Maturity Corporate Bond Index, FTSE Canada 2029 Maturity Corporate Bond Index and FTSE Canada 2030 Maturity Corporate Bond Index (collectively, the "FTSE Maturity Corporate Bond Indices") vest in the relevant LSE Group company which owns the FTSE Maturity Corporate Bond Indices. "FTSE®" is a trade mark of the relevant LSE Group company and is used by any other LSE Group company under license. The FTSE Maturity Corporate Bond Indices are calculated by or on behalf of FTSE Global Debt Capital Markets Inc. or its affiliate, agent or partner. The LSE Group does not accept any liability whatsoever to any person arising out of (a) the use of, reliance on or any error in the FTSE Maturity Corporate Bond Indices or (b) investment in or operation of the Canadian TMCB ETFs. The LSE Group makes no claim, prediction, warranty or representation either as to the results to be obtained from the Canadian TMCB ETFs or the suitability of the FTSE Maturity Corporate Bond Indices for the purpose to which they are being put by RBC GAM Inc. RBC Canadian Bank Yield Index ETF, RBC U.S. Banks Yield Index ETF, and RBC U.S. Banks Yield (CAD Hedged) Index ETF have been developed solely by RBC GAM Inc. and are not sponsored, promoted, sold or supported by Solactive AG ("Solactive"). Solactive Canada Bank Yield Index, Solactive U.S. Bank Yield NTR Index and Solactive U.S. Bank Yield NTR (CAD Hedged) Index are calculated and published by Solactive. Solactive does not offer any express or implicit guarantee or assurance regarding the results to be obtained from the use of the index or index price nor does Solactive make any representation regarding the advisability of investing in the ETFs. About RBC Royal Bank of Canada is a global financial institution with a purpose-driven, principles-led approach to delivering leading performance. Our success comes from the 98,000+ employees who leverage their imaginations and insights to bring our vision, values and strategy to life so we can help our clients thrive and communities prosper. As Canada's biggest bank and one of the largest in the world, based on market capitalization, we have a diversified business model with a focus on innovation and providing exceptional experiences to our more than 18 million clients in Canada , the U.S. and 27 other countries. Learn more at rbc.com . We are proud to support a broad range of community initiatives through donations, community investments and employee volunteer activities. See how at rbc.com/peopleandplanet . About RBC Global Asset Management RBC Global Asset Management (RBC GAM) is the asset management division of Royal Bank of Canada (RBC). RBC GAM is a provider of global investment management services and solutions to institutional, high-net-worth and individual investors through separate accounts, pooled funds, mutual funds, hedge funds, exchange-traded funds and specialty investment strategies. RBC Funds, BlueBay Funds, PH&N Funds and RBC ETFs are offered by RBC Global Asset Management Inc. (RBC GAM Inc.) and distributed through authorized dealers in Canada . The RBC GAM group of companies, which includes RBC GAM Inc. (including PH&N Institutional) and RBC Indigo Asset Management Inc., manage approximately $680 billion in assets and have approximately 1,600 employees located across Canada , the United States , Europe and Asia . For more information, please contact: Brandon Dorey , RBC GAM Corporate Communications, 647-262-6307, brandon.dorey@rbc.com SOURCE RBC Global Asset Management Inc. View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2024/19/c6545.html © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
By Jim Rossman, Tribune News Service (TNS) Everyone seems to be listening to something. I’m not sure what they’re listening to, because they all seem to be wearing headphones. I suppose they’re all listening to their favorite podcast or just their playlists. Here are a few gift suggestions for headphones that’ll make anything sound better. I’ve listed the retail pricing, but don’t be surprised if you find them on sale. We’ve all tried traditional earbuds. They can sound good if the fit is correct. The SoundCore AreoFit 2 ($99.99, soundcore.com) don’t fit inside your ear canal. Instead, they sit on the outside of your ear. The battery sits behind your ear, much like a hearing aid. The speaker is attached by a sturdy, yet flexible cable. The only adjustment is on the speaker end – it clicks to adjust the angle of the speaker to sit directly over your ear canal. The fact that they don’t insert into your ears means you can still hear the outside world, so you are not so isolated. These are great for jogging or biking. The sound is really nice. The full range of sound comes in very clearly and the form factor is comfortable to wear, even for hours at a time. There are four microphones, so your voice sounds clear on phone calls. They have an IP55 rating, so they can withstand water spashing, sweat or dust. They can also connect to more than one device, so you can keep them paired to your phone and laptop and switch easily between them. The AeroFit 2 can play for 10 hours on a charge. They live in a battery case that can keep them charged for more than 40 hours. The charging case can power up via a USB-C port or a Qi wireless charger. They are available in white, blue, green or black. The Soundcore C40i ($99.99, soundcore.com) is another fun option in a non-traditional form factor. Instead of going inside or even over the top your ears, the C40i earbuds are u-shaped and they clip on the sides of your ears. They are unlike anything I’ve ever tried, and they sounded surprisingly good once you get them in the right spot. They are a bit flexible, in that you can pull them apart slightly to get them in the right spot. Once you let go, they gently grip your earlobe. I must admit I was a little self-conscious when I first started wearing the C40i earbuds, as they look a bit like earrings. The fit is interesting. The end with the speaker sits in front of your ear canal and the end with the battery and action button goes behind your ear. You can adjust them on your ear until the sound becomes clear. It’ll be obvious to your ears when you have them adjusted correctly. If your earlobes are thin, there are some rubber sleeves that can help with the fit. You want them to be snug, but not to the point where they are pinching your ears. There is a customizable button on the back of each earbud for call and music control. They are on the small side, so the battery life is seven hours before needing to return to the case for a charge. The case can charge them twice more before it needs recharging. The case charges via USB-C cable, but it is too small for wireless chargers. The earbuds have a 12mm x 17mm oval shaped driver and the sound quality is very good. Voice quality on phone calls also surprised me with its clarity. They sync with the Soundcore phone app to let you assign the button commands and tweak the sound settings. They also can pair to two devices at once. Frequent flyers know all about noise canceling over-the-ear headphones. These headphones usually have active noise canceling, which uses microphones to listen to the ambient noise and reduce it before it can get to your ears. What I’m noticing is more and more people wearing these during workouts or just walking around. The Baseus Bowie 30 Max noise canceling headphones ($79.99, baseus.com) are fairly generic looking headphones, but their performance is incredible for the price. Baseus says the Bowie 30s can eliminate 96 percent of noise, but that actual noise cancellation will vary depending on the ambient noise level. I can tell you the noise canceling is impressive. There is also a transparency mode that lets in outside sounds so you can have a conversation with someone without taking them off. You can pair them to the free Baseus phone app to unlock some additional features including spatial acoustics, bass enhancement and low-latency mode. These connect to your phone or PC wirelessly via Bluetooth or wired with an included 3.5mm cable. They last an impressive 65 hours on a charge without noise canceling or 50 hours with noise canceling enabled. The ear cups and piece that fits over the top of your head are nicely padded and the entire headset folds up to take up less room in your bag. ©2024 Tribune Content Agency, LLC.NEW YORK — President- elect Donald Trump wants to turn the lights out on daylight saving time . In a post on his social media site Friday, Trump said his party would try to end the practice when he returns to office. “The Republican Party will use its best efforts to eliminate Daylight Saving Time, which has a small but strong constituency, but shouldn’t! Daylight Saving Time is inconvenient, and very costly to our Nation,” he wrote. Setting clocks forward one hour in the spring and back an hour in the fall is intended to maximize daylight during summer months, but has long been subject to scrutiny. Daylight saving time was first adopted as a wartime measure in 1942. Lawmakers have occasionally proposed getting rid of the time change altogether. The most prominent recent attempt, a now-stalled bipartisan bill named the Sunshine Protection Act , had proposed making daylight saving time permanent. The measure was sponsored by Florida Sen. Marco Rubio , whom Trump has tapped to helm the State Department. “Changing the clock twice a year is outdated and unnecessary,” Republican Sen. Rick Scott of Florida said as the Senate voted in favor of the measure. Health experts have said that lawmakers have it backward and that standard time should be made permanent. Some health groups , including the American Medical Association and American Academy of Sleep Medicine, have said that it’s time to do away with time switches and that sticking with standard time aligns better with the sun — and human biology. Most countries do not observe daylight saving time. For those that do, the date that clocks are changed varies, creating a complicated tapestry of changing time differences. Arizona and Hawaii don't change their clocks at all.Wallbox Receives Notice of Non-Compliance with NYSE Trading Share Price Listing Rule
NoneNew collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDerm Cohealyx expected to triple AVITA Medical’s addressable market in burns VALENCIA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Cohealyx TM , a new collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. Cohealyx is designed for tissue integration and revascularization to facilitate wound healing, reduce treatment timelines, and improve patient outcomes in the treatment of full-thickness wounds. Burns and full-thickness wounds penetrate all layers of the skin, resulting in significant tissue loss and structural damage. Unlike superficial wounds, full-thickness wounds lack the cellular components and structural support necessary to regenerate missing tissue. Without timely surgical intervention, there is heightened risk of delayed closure, infection, and severe scarring. Dermal matrices are essential in two-stage procedures for treating these wounds, as they support tissue generation for successful skin graft take and improve healing outcomes. Cohealyx addresses this critical need in the treatment of full-thickness wounds with an advanced bovine collagen-based design engineered to facilitate cellular migration and blood vessel formation. Preclinical studies in porcine models demonstrated that Cohealyx generated robust tissue capable of consistently supporting a split-thickness skin graft in a two-stage procedure earlier than leading dermal matrices in the study. While animal model results do not necessarily translate to clinical results, this expedited timeline is anticipated to lead to quicker wound closure and streamlined clinician workflows, resulting in shorter hospital stays, reduced treatment costs, and better patient outcomes. These parameters will be evaluated in a clinical study. “Cohealyx is a strategic addition to our RECELL-centric portfolio, unlocking the powerful synergies of RECELL and Cohealyx to address full-thickness wounds,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “This expansion to our product portfolio strengthens our ability to deliver superior patient outcomes and significantly expands our commercial potential in burns. By equipping clinicians with more comprehensive treatment options, we strengthen our competitive position, drive new growth opportunities, and further our commitment to advancing regenerative medicine.” Cohealyx strengthens AVITA Medical’s portfolio by expanding its capabilities in the treatment of full-thickness wounds. Offered alongside RECELL and PermeaDerm ® , Cohealyx enhances our comprehensive portfolio for addressing full-thickness wound care. This expanded portfolio is expected to triple AVITA Medical’s addressable market in burns, as dermal matrices are a critical component of the standard two-stage surgical procedure for definitive closure of these wounds. We also anticipate Cohealyx will generate significant revenue as we penetrate the full-thickness skin defect market. AVITA Medical plans to develop clinical data for Cohealyx in early 2025 to build on the preclinical success and support the product’s commercial launch. The post-market clinical study will assess Cohealyx’s performance in real-world settings, focusing on clinical efficacy and cost savings in the treatment of full-thickness wounds and burns. In the U.S., we expect to launch full commercialization efforts in the beginning of the second quarter of 2025. About AVITA Medical, Inc. AVITA Medical is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL System, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin TM Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. In the United States, AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm, a biosynthetic wound matrix, and Cohealyx, an AVITA Medical-branded collagen-based dermal matrix. In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System, excluding RECELL GO TM , is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan. To learn more, visit www.avitamedical.com . About Regenity Biosciences Regenity Biosciences, a Linden Capital Partners portfolio company, is a leading global developer and manufacturer of bioresorbable technologies to repair and regenerate natural tissue and bone for a variety of markets including dental, spine, orthopaedic, sports medicine, advanced wound, neurosurgery, ENT, and nerve repair. Founded in 1997, Regenity (formerly Collagen Matrix, Inc.) is headquartered in Paramus, New Jersey, with manufacturing locations in Oakland and Allendale, New Jersey and Groningen, the Netherlands. Regenity's product portfolio includes a variety of collagen-based and synthetic polymer solutions that support the company's platform for tissue and bone regeneration. Regenity develops proprietary products that are sold to OEM customers on either a contract or private label basis and offers partnership opportunities including contract product development and manufacturing services. For more information, please visit www.regenity.com . Forward-Looking Statements Th is press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “would,” “may,” “will,” “believe,” “continue,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “outlook,” “guidance,” “future,” and similar words or expressions, and the use of future dates. Forward-looking statements include, but are not limited to, statements relating to the timing and realization of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; anticipated market share growth and revenue generation from certain products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company’s control. These statements are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the “Risk Factors” section of the Company’s latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties. Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.